213 related articles for article (PubMed ID: 28889403)
1. Do Paediatric Investigation Plans (PIPs) Advance Paediatric Healthcare?
Rose K; Walson PD
Paediatr Drugs; 2017 Dec; 19(6):515-522. PubMed ID: 28889403
[TBL] [Abstract][Full Text] [Related]
2. European Union pediatric legislation jeopardizes worldwide, timely future advances in the care of children with cancer.
Rose K
Clin Ther; 2014 Feb; 36(2):163-77. PubMed ID: 24529288
[TBL] [Abstract][Full Text] [Related]
3. The Meanings of "Pediatric Drug Development".
Rose K; Grant-Kels JM
Ther Innov Regul Sci; 2019 Nov; 53(6):767-774. PubMed ID: 30526039
[TBL] [Abstract][Full Text] [Related]
4. Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committee--adolescents' melanoma as a paradigm.
Rose K; Senn S
Pharm Stat; 2014; 13(4):211-3. PubMed ID: 24903307
[TBL] [Abstract][Full Text] [Related]
5. Do the European Medicines Agency Decisions Hurt Pediatric Melanoma Patients?
Rose K; Walson PD
Clin Ther; 2017 Feb; 39(2):253-265. PubMed ID: 28159363
[TBL] [Abstract][Full Text] [Related]
6. Pediatric investigation plans for specific immunotherapy: Questionable contributions to childhood health.
Rose K; Kopp MV
Pediatr Allergy Immunol; 2015 Dec; 26(8):695-701. PubMed ID: 26495999
[TBL] [Abstract][Full Text] [Related]
7. Three years of paediatric regulation in the European Union.
Olski TM; Lampus SF; Gherarducci G; Saint Raymond A
Eur J Clin Pharmacol; 2011 Mar; 67(3):245-52. PubMed ID: 21286912
[TBL] [Abstract][Full Text] [Related]
8. Enabling Development of Paediatric Medicines in Europe: 10 Years of the EU Paediatric Regulation.
Tomasi PA; Egger GF; Pallidis C; Saint-Raymond A
Paediatr Drugs; 2017 Dec; 19(6):505-513. PubMed ID: 28900869
[TBL] [Abstract][Full Text] [Related]
9. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
Pflieger M; Bertram D
Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
[TBL] [Abstract][Full Text] [Related]
10. Creating a unique, multi-stakeholder Paediatric Oncology Platform to improve drug development for children and adolescents with cancer.
Vassal G; Rousseau R; Blanc P; Moreno L; Bode G; Schwoch S; Schrappe M; Skolnik J; Bergman L; Bradley-Garelik MB; Saha V; Pearson A; Zwierzina H
Eur J Cancer; 2015 Jan; 51(2):218-24. PubMed ID: 25434924
[TBL] [Abstract][Full Text] [Related]
11. More than 5 years of European Paediatric Regulation: statistics and industrial experience.
Winzenburg G
Int J Pharm; 2014 Aug; 469(2):260-2. PubMed ID: 24704106
[TBL] [Abstract][Full Text] [Related]
12. The impact of legislation on drug substances used off-label in paediatric wards--a nationwide study.
Haslund-Krog S; Mathiasen R; Christensen HR; Holst H
Eur J Clin Pharmacol; 2014 Apr; 70(4):445-52. PubMed ID: 24398969
[TBL] [Abstract][Full Text] [Related]
13. Paediatric investigation plans for pain: painfully slow!
Davies EH; Ollivier CM; Saint Raymond A
Eur J Clin Pharmacol; 2010 Nov; 66(11):1091-7. PubMed ID: 20821198
[TBL] [Abstract][Full Text] [Related]
14. Review of the Best Pharmaceuticals for Children Act and the Pediatric Research Equity Act: What can the obstetric community learn from the pediatric experience?
Ren Z; Zajicek A
Semin Perinatol; 2015 Nov; 39(7):530-1. PubMed ID: 26455383
[TBL] [Abstract][Full Text] [Related]
15. Extrapolation in the development of paediatric medicines: examples from approvals for biological treatments for paediatric chronic immune-mediated inflammatory diseases.
Stefanska AM; Distlerová D; Musaus J; Olski TM; Dunder K; Salmonson T; Mentzer D; Müller-Berghaus J; Hemmings R; Veselý R
Arch Dis Child; 2017 Oct; 102(10):952-957. PubMed ID: 28554892
[TBL] [Abstract][Full Text] [Related]
16. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
[TBL] [Abstract][Full Text] [Related]
17. The Challenges of Pediatric Drug Development.
Rose K
Curr Ther Res Clin Exp; 2019; 90():128-134. PubMed ID: 31388368
[TBL] [Abstract][Full Text] [Related]
18. The EU paediatric regulation: still a large discrepancy between therapeutic needs and approved paediatric investigation plans.
Wimmer S; Rascher W; McCarthy S; Neubert A
Paediatr Drugs; 2014 Oct; 16(5):397-406. PubMed ID: 25056717
[TBL] [Abstract][Full Text] [Related]
19. Juvenile animal studies and pediatric drug development: a European regulatory perspective.
Carleer J; Karres J
Birth Defects Res B Dev Reprod Toxicol; 2011 Aug; 92(4):254-60. PubMed ID: 21638754
[TBL] [Abstract][Full Text] [Related]
20. The contributions of the European Medicines Agency and its pediatric committee to the fight against childhood leukemia.
Rose K; Walson PD
Risk Manag Healthc Policy; 2015; 8():185-205. PubMed ID: 26604845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
